Development of the Commercial Manufacturing Process for Ipatasertib
Keywords:Biocatalysis, Catalysis, Drug development, Enzyme, Green chemistry, Metal catalysis
Ipatasertib is a potent small molecule Akt kinase inhibitor currently tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the commercial manufacturing process is given. The convergent synthesis consists of ten steps with eight isolated intermediates and utilizes a wide range of chemical techniques and technologies to build-up this complex drug. All three stereocenters are introduced using enzyme or metal catalysis.
How to Cite
Copyright (c) 2021 Andreas Schuster
This work is licensed under a Creative Commons Attribution 4.0 International License.